These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
274 related articles for article (PubMed ID: 31529984)
1. Jurisdictional Guidance on DOAC Use-Will It Affect Practice? A Comparison of European, American, and Canadian Product Monographs. Lamb DA; Bungard TJ; Lowerison J; Semchuk WM; Thomson P; Brocklebank C; Bolt J Ann Pharmacother; 2020 Mar; 54(3):277-282. PubMed ID: 31529984 [No Abstract] [Full Text] [Related]
2. Facing real-life with direct oral anticoagulants in patients with nonvalvular atrial fibrillation: outcomes from the first observational and prospective study in a Spanish population. Cerdá M; Cerezo-Manchado JJ; Johansson E; Martínez F; Fernández M; Varela A; Rodríguez S; Bosch F; Santamaría A J Comp Eff Res; 2019 Feb; 8(3):165-178. PubMed ID: 30654626 [TBL] [Abstract][Full Text] [Related]
3. Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis. Gómez-Outes A; Terleira-Fernández AI; Lecumberri R; Suárez-Gea ML; Vargas-Castrillón E Thromb Res; 2014 Oct; 134(4):774-82. PubMed ID: 25037495 [TBL] [Abstract][Full Text] [Related]
4. Ninety-day prognosis of patients receiving direct oral anticoagulants in the early phase of non valvular atrial fibrillation-related acute ischemic stroke: The real life evidence. Masotti L; Grifoni E; Dei A; Vannucchi V; Moroni F; Spolveri S; Panigada G; Landini G Thromb Res; 2018 Dec; 172():165-168. PubMed ID: 30419471 [No Abstract] [Full Text] [Related]
6. Considerations for Prescribing Target-Specific Oral Anticoagulants in the Setting of Renal Dysfunction or Drug Interactions. Pan EY; Sobieraj DM Conn Med; 2016 Feb; 80(2):105-11. PubMed ID: 27024982 [No Abstract] [Full Text] [Related]
7. Suboptimal Use of Oral Anticoagulants in Atrial Fibrillation: Has the Introduction of Direct Oral Anticoagulants Improved Prescribing Practices? Alamneh EA; Chalmers L; Bereznicki LR Am J Cardiovasc Drugs; 2016 Jun; 16(3):183-200. PubMed ID: 26862063 [TBL] [Abstract][Full Text] [Related]
8. Challenges and Treatment for Stroke Prophylaxis in Patients with Atrial Fibrillation in Mexico: A Review. Alcocer L Am J Cardiovasc Drugs; 2016 Jun; 16(3):171-82. PubMed ID: 26923792 [TBL] [Abstract][Full Text] [Related]
9. Impact of new oral anticoagulants on gastrointestinal bleeding in atrial fibrillation: A meta-analysis of interventional trials. Loffredo L; Perri L; Violi F Dig Liver Dis; 2015 May; 47(5):429-31. PubMed ID: 25732432 [TBL] [Abstract][Full Text] [Related]
10. Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups. Lip GY; Mitchell SA; Liu X; Liu LZ; Phatak H; Kachroo S; Batson S Int J Cardiol; 2016 Feb; 204():88-94. PubMed ID: 26655548 [TBL] [Abstract][Full Text] [Related]
11. Management of Venous Thromboembolism: Recent Advances in Oral Anticoagulation Therapy. Finks SW; Trujillo TC; Dobesh PP Ann Pharmacother; 2016 Jun; 50(6):486-501. PubMed ID: 26917821 [TBL] [Abstract][Full Text] [Related]
12. Bleeding Risk of Add-On Anti-Platelet Agents to Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation (From 2216 Patients in the DIRECT Registry). Sotomi Y; Hirata A; Amiya R; Kobayashi T; Hirayama A; Sakata Y; Higuchi Y Am J Cardiol; 2019 Apr; 123(8):1293-1300. PubMed ID: 30717887 [TBL] [Abstract][Full Text] [Related]
13. Comparative study of hemorrhagic and ischemic complications among anticoagulants in patients undergoing cryoballoon ablation for atrial fibrillation. Okishige K; Nakamura T; Aoyagi H; Kawaguchi N; Yamashita M; Kurabayashi M; Suzuki H; Asano M; Shimura T; Yamauchi Y; Sasano T; Hirao K J Cardiol; 2017 Jan; 69(1):11-15. PubMed ID: 27160710 [TBL] [Abstract][Full Text] [Related]
14. [Treatment of bleeding complications due to oral anticoagulant drugs]. Riess H Laryngorhinootologie; 2015 Oct; 94(10):697-709. PubMed ID: 26468622 [No Abstract] [Full Text] [Related]
15. [Analysis of the Risk Factors Associated with Minor Bleeding in Patients with Venous Thromboembolism during Treatment with Direct Oral Anticoagulants]. Sunaga T; Shimizu T; Nakamura S; Takahashi N; Higashino M; Matsui M; Hozumi T; Ebato M; Suzuki H; Kogo M; Watanabe T; Sasaki T Yakugaku Zasshi; 2019; 139(3):461-467. PubMed ID: 30828024 [TBL] [Abstract][Full Text] [Related]
16. New Oral Anticoagulants: What Prescribers Should Know; Differences and Similarities between Warfarin and "New Agents" (Dabigatran, Rivaroxaban, Apixaban, Edoxaban) - Review of Indications, Contraindications and Safety of Use. Petrasko M; Raizada A; Petraskova T S D Med; 2016 Aug; 69(8):363-369. PubMed ID: 28806005 [No Abstract] [Full Text] [Related]
17. Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis. Cohen AT; Hamilton M; Mitchell SA; Phatak H; Liu X; Bird A; Tushabe D; Batson S PLoS One; 2015; 10(12):e0144856. PubMed ID: 26716830 [TBL] [Abstract][Full Text] [Related]